Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 17,410,899 $ 17,958,989
Other receivable from joint venture 0 400,000
Prepaid expenses and other current assets 164,652 47,371
Total Current Assets 17,575,551 18,406,360
Other Assets    
Patent costs 1,825,326 1,798,484
Total Assets 19,400,877 20,204,844
Current Liabilities    
Accounts payable and accrued liabilities 1,815,791 350,299
Total Current Liabilities 1,815,791 350,299
Stockholders' Equity    
Common stock, $0.001 par value, 8,333,333 authorized, 4,416,961 and 3,252,371 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 4,417 3,252
Additional paid-in capital 139,121,290 133,932,615
Accumulated deficit (121,544,000) (114,084,746)
Total Stockholders' Equity 17,585,086 19,854,545
Total Liabilities and Stockholders' Equity 19,400,877 20,204,844
Preferred Stock Series A [Member]    
Stockholders' Equity    
Preferred stock value 712 757
Series B Preferred Shares [Member]    
Stockholders' Equity    
Preferred stock value $ 2,667 $ 2,667